Global /United States /Healthcare /Drug Manufacturers - General /BCAX

Bicara Therapeutics Inc.

BCAX

• NASDAQ: BCAX • Delayed

21.28USD -2.9%

As of 13 June 2026, Bicara Therapeutics Inc. has a market cap of $1.39B USD, ranking #8857 globally and #1940 in the United States. It ranks #745 in the Healthcare sector, and #279 in the Drug Manufacturers - General industry.

Global Rank

8857

Country Rank

1940

Sector Rank

745

Industry Rank

279

Key Stats

Market Cap

$1.39BUSD

Enterprise Value

$980.05MUSD

EBITDA (TTM)

-$155.5MUSD

Net Income (TTM)

-$137.95MUSD

PB Ratio

2.9

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Claire Mazumdar Clemon open_in_new

Employees

103

Founded

2018

IPO

13 Sep 2024

Website

bicara.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.9%	-9.9%	16%	28%	25%	26%	44%	-17%	-17%

News

BCAX Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	BCAX Bicara Therapeutics Inc ISIN: US0554771032 Shares Out.: Shares Outstanding: 65.704M¹ Shares Float: 37.557M² TV: TradingView: NASDAQ: BCAX SA: Stock Analysis: NASDAQ: BCAX YF: Yahoo Finance: BCAX GF: Google Finance: NASDAQ: BCAX NQ: NASDAQ: BCAX BA: Barron's: BCAX MS: Morningstar: XNAS: BCAX	21.28 USD	TV: TradingView: NASDAQ: BCAX SA: Stock Analysis: NASDAQ: BCAX YF: Yahoo Finance: BCAX GF: Google Finance: NASDAQ: BCAX NQ: NASDAQ: BCAX BA: Barron's: BCAX MS: Morningstar: XNAS: BCAX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 55K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 39K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 26K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 20K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 11K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 8K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 23K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 21K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 20K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 13K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 8K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 8K%	14.6	United Kingdom

chevron_leftBack